GlassScriptPhysician profile
Steven Poertner
NPI 1467834143
$2,095.15
in general payments reported to CMS, 2019-2025
20 companies · $1,077 in 2025
The $1,077 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $163 · 2024: $856 · 2025: $1,077.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,095.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,095.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $616.93 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $428.48 | 2024-2025 | Krystexxa, Repatha, Repatha |
| Lilly USA, LLC | $179.63 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Inari Medical, INC. | $121.50 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Astellas Pharma US INC | $96.02 | 2024-2025 | Veozah |
| Exact Sciences Corporation | $92.23 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Abbott Laboratories | $73.20 | 2024-2025 | Freestyle Libre 3 |
| Abbvie INC. | $65.93 | 2025 | |
| Aimmune Therapeutics, INC. | $62.33 | 2024-2025 | Zenpep |
| Glaxosmithkline, LLC. | $53.34 | 2024-2025 | Shingrix, Arexvy |
| Intra-Sana Laboratories | $50.34 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Bayer Healthcare Pharmaceuticals INC. | $39.35 | 2025 | |
| Phathom Pharmaceuticals, INC. | $38.18 | 2025 | Voquezna |
| Daiichi Sankyo INC. | $35.35 | 2024-2025 | Injectafer |
| Pfizer INC. | $32.98 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $28.43 | 2024-2025 | Zoryve |
| Astrazeneca Pharmaceuticals LP | $25.80 | 2024 | |
| Xeris Pharmaceuticals, INC. | $23.49 | 2025 | Keveyis |
| Lundbeck LLC | $16.31 | 2024 | Rexulti |
| Dexcom, INC. | $15.33 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Poertner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.